FOXO1A/3A (Phospho-Ser322+Ser325) antibody
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱: FOXO1A/3A (Phospho-Ser322+Ser325) antibody
產(chǎn)品型號:
產(chǎn)品展商: immunoclone
產(chǎn)品文檔: 無相關(guān)文檔
簡單介紹
FOXO1A/3A (Phospho-Ser322+Ser325) antibody迅速增長的產(chǎn)品線包括一抗、二抗、**測定及細(xì)胞檢測試劑盒、蛋白/多肽、激動劑/拮抗劑/活化劑/抑制劑及裂解物等。FOXO1A/3A (Phospho-Ser322+Ser325) antibody嚴(yán)格的質(zhì)量控制和驗(yàn)證實(shí)驗(yàn)包括各種不同的應(yīng)用：WB、細(xì)胞**熒光、**組化、流式細(xì)胞術(shù)、ELISA、CHIP、IP和peptide array。
FOXO1A/3A (Phospho-Ser322+Ser325) antibody
的詳細(xì)介紹
FOXO1A/3A (Phospho-Ser322+Ser325) antibodyProduct Profile
|
Product Name
|
Rabbit anti-FOXO1A/3A (Phospho-Ser322+Ser325) polyclonal antibody
|
|
Antibody Type
|
Primary Antibodies
|
|
Immunogen
|
The antiserum was produced against synthesized peptide derived from human FOXO1A/3A around the phosphorylation site of Ser322 and Ser325.
|
FOXO1A/3A (Phospho-Ser322+Ser325) antibodyKey Feature
|
Clonality
|
Polyclonal
|
|
Host Species
|
Rabbit
|
|
Tested Applications
|
WBELISA
|
|
|
WB:1:500~1:1000
ELISA:1:1000
|
|
Species Reactivity
|
HumanMouse
|
|
Concentration
|
1 mg/ml
|
|
Purification
|
Affinity purified
|
FOXO1A/3A (Phospho-Ser322+Ser325) antibodyTarget Information
|
Gene Symbol
|
FOXO1
|
|
Gene Synonyms
|
FKHR
forkhead box O1A (FKHR)
Forkhead box protein O1A
Forkhead in rhabdomyosarcoma
FOXO1
More
|
FOXO1A/3A (Phospho-Ser322+Ser325) antibodyDatabase Links
|
Entrez Gene
|
2308
|
|
Unigene
|
370666
|
|
OMIM
|
136533
268220
|
|
SwissProt ID
|
Q12778
|
FOXO1A/3A (Phospho-Ser322+Ser325) antibodyApplication
-
Western blot
Western blot analysis of extracts from NIH-3T3 cells treated with Wortmannin 40nM 24h, using FOXO1A/3A (Phospho-Ser322+Ser325) Antibody. The lane on the right is treated with the synthesized peptide
|
Application Notes
|
WB:1:500~1:1000
ELISA:1:1000
|
Additional Information
|
Form
|
Liquid
|
|
Storage Instructions
|
store at -20°C. Avoid repeated freeze / thaw cycles
|
|
Storage Buffer
|
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
|